BRCA Gene Changes: Cancer Risk and Genetic Testing
A positive test result indicates that a person has a harmful change in BRCA1 or BRCA2 (these are typically called “pathogenic” or “likely pathogenic” variants on laboratory test reports) and has …
BRCA1 and BRCA2 (PDQ®) - NCI - National Cancer Institute
Evidence-based, expert-reviewed summary about the BRCA1 and BRCA2 genes and hereditary breast and ovarian cancer. This summary also contains information about the cancer risks …
Mutaciones en el gen BRCA: el riesgo de cáncer y las pruebas …
El BRCA1 y el BRCA2 a veces se conocen como genes supresores de tumores porque cuando tienen cambios específicos, llamados variantes (o mutaciones) dañinas (o patógenas), es …
Cancer Risk for Women Carrying BRCA Mutations - NCI
Jul 12, 2017 · For mutations in both BRCA genes, the risk of ovarian cancer increased with increasing age, until women reached ages 61–70. The cumulative risk estimates for …
Surgery to Reduce the Risk of Breast Cancer - National Cancer …
Risk-reducing (also called preventive or prophylactic) surgery can lower the risk of breast cancer in people who are at very high risk, such as women who carry a harmful mutation in a breast …
MRI, Surgery Reduce Cancer Deaths in Women with BRCA Changes
Apr 15, 2024 · For women with inherited harmful changes in BRCA genes, MRI surveillance and salpingo-oophorectomy can modestly reduce their risk of dying from breast and ovarian …
Breast Cancer Risk Assessment Calculator - NCI
Does the woman have a mutation in either the BRCA1 or BRCA2 gene, or a diagnosis of a genetic syndrome that may be associated with elevated risk of breast cancer?
BRCA Testing in Young Cancer Patients - NCI - National Cancer …
Mar 1, 2016 · Testing for genetic mutations strongly associated with an increased breast cancer risk has risen dramatically among women younger than age 40 who are diagnosed with the …
Olaparib Approved for Breast Cancers with BRCA Gene Mutations
Jan 29, 2018 · The Food and Drug Administration has approved olaparib (Lynparza®) to treat metastatic breast cancers that have inherited mutations in the BRCA1 or BRCA2 genes as …
Olaparib for Pancreatic Cancer with BRCA Mutations - NCI
Jun 26, 2019 · Olaparib (Lynparza) may benefit some people with advanced pancreatic cancer who have BRCA1 or BRCA2 mutations, according to the POLO trial results.
- Some results have been removed